PSI CRO, a leading clinical research organization, has significantly enhanced clinical trial site selection using SYNETIC™, an AI-driven platform based on the Arango Contextual Data Platform. This innovative solution has cut the site identification process from six weeks to mere minutes by unifying fragmented clinical data into a contextual layer. By quickly identifying high-performing trial sites and minimizing costly non-enrolling institutions, PSI CRO aims to save millions in operational costs, which can exceed $160 per minute during drug development. SYNETIC™ offers explainable insights for site selection, reinforcing trust in AI recommendations through transparency. The platform supports efficient recruitment, addressing the industry challenge where 30-40% of sites under-enroll. Arango’s multimodel capabilities provide a robust foundation for data-driven decision-making in clinical research, helping organizations streamline their operations and optimize resource allocation. Learn more about PSI CRO and Arango’s transformative impact on clinical trials at arango.ai.
Source link
